SPECIAL NOTICE

We are working on upgrading our websites and despite our best endeavours have experienced census type calamities for almost a week now. Our apologies, we hope to have all problems resolved by Monday August 15th.

SEARCH LISTED COMPANY


Any AUS or NZ company

BROWSE

Browse Australian listed companies

0-9A B C D E F G H I J K L M N O P Q R S T U V W XY Z

Browse current Australian managed funds

0-9A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

SEARCH PRIVATE COMPANY


SEARCH FUNDS

Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:

PHARMAUST LIMITED(PAA)

Click here for free access to this company's:
ASX, Legal & CGT Status

Former (or subsequent) names

 FROMTO
PHARMAUST LIMITED26/11/2004
ECHO TECHNOLOGIES LIMITED26/11/2004

Shareholder links

Our website ranking of PAA: rating 5
(5 out of 5)
COMPANY WEBSITE:

 

REGISTRY:

Computershare, Level 11, 172 St Georges Terrace, Perth WA 6000

Tel : +61 (0)3 9415 4000 or 1300 850 505 (within Australia)
Fax : +61 3 9473 2500
RegistryWebsite RegistryEmail

Company details

ISIN: AU000000PAA1
Address: Suite 39, 1 Freshwater Parade Claremont, Western Australia
Tel:  +61 8 6364 0899 Fax: +61 8 9467 6111

Date first listed: 05/10/2001
Company Secretary: Mr Sam Wright
Sector: Pharmaceuticals & Biotechnology Industry Group: XHJ
Activities: Contract drug discovery and development, manufacturing, sales, and marketing of healthcare and pharmaceutical products

News & Events

Expand this box to read and print

The suspension of trading in the securities of PharmAust will be lifted from the commencement of trading on Thursday, 18 June 2020, following the release by PAA of an announcement regarding results from SARS-CoV-2 repeat preliminary experiments.

18/06/2020

Monepantel and monepantel sulfone treatment both reduce SARS-CoV-2 (COVID-19) cell-to-cell infectivity in cell culture in a repeat preliminary experimental evaluation. Repeat preliminary experiment data demonstrate suppression of virus infectivity by approximately 95% in cell culture by each drug. Preparations are being made for Phase 1 trial.

18/06/2020

The securities of PharmAust Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of PAA, pending the release of an announcement regarding disclosure of results from the SARS-CoV-2 repeat experiments.

15/06/2020

The suspension of trading in the securities of PharmAust Limited will be lifted immediately following the release by PAA of an announcement regarding disclosure of preliminary results from a pre-clinical trial.

04/06/2020

Monepantel treatment reduces SARS-CoV-2 virus replication in tissue culture (based upon preliminary experiments). Monepantel treatment reduces SARS-CoV-2 cell-to-cell infectivity in tissue culture (based upon preliminary experiments). Promising early data demonstrating suppression of virus by 50-95% requires further confirmation in repeat and more comprehensive studies.

04/06/2020

The securities of PharmAust Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of PAA, pending the release of an announcement regarding disclosure of preliminary results from a pre-clinical trial.

02/06/2020

we understand that on or about this date the company consolidated its shares 1 for 20

12/11/2015

we understand that on or about this date the company made an in specie distribution of 1 share in Diashi Mining Limited for every 29.24 shares in the company

22/11/2012

shares reinstated to quotation

18/10/2007

lodges 2007 Annual Report and confirms its Announcement of 28 September 2007 that it had been unable to lodge its Full Final Accounts due to the failure of its 40% owned subsidiary, Commonwealth Biotechnologies Inc ("BI"), to provide audited figures in confirmation of its final management accounts

12/10/2007

the application for an interlocutory injunction brought by Chimaera Capital Limited ("himaera") against the Company's current Entitlement Issue was dismissed in the Federal Court yesterday - despite the company requesting information from Commonwealth Biotechnologies Inc ("BI") (of which Dr D'Sylva remains Managing Director) since mid-July 2007 - it has still not received it - this is the only reason for the Company's suspension

05/10/2007

shares suspended from quotation as the company failed to lodge its financial statements

02/10/2007

shares reinstated to quotation

14/02/2007

ADVANCE HEALTHCARE GROUP LIMITED has deferred an equity placement to raise $400,000 until Pharmaust's position in relation to its proposed takeover announced on 5 January 2007 has been clarified

13/02/2007

shares suspended from quotation pending release of an announcement

09/02/2007

name changed from Echo Technologies Limited

26/11/2004
OFX Transferring Money Internationally to Free

 

Click here for free access to this company's:
ASX, Legal & CGT Status

Your comments

Please read our Terms before viewing comments.

 

Company Updates

Post your comments here

Please read our Terms before posting comments.
OMISSIONS
    You can post a comment here about this company

    Please click in the "I'm not a robot" box and enter the word/figures you see in the image that then appears.

    loading Posting your comments. Please wait...

     


     

    Click here for free access to this company's:
    ASX, Legal & CGT Status

    Directors' on-market share transactions (last 5)

    rss feeds

    Purchases Sales

    DATEDIRECTORNUMBERPRICEAMOUNT
    24/08/2021Sam Wright500,000$0.085$42,500
    16/08/2019Sam Wright200,000$0.074$14,850
    26/06/2018Robert Bishop500,000$0.040$20,000
    26/06/2018Sam Wright500,000$0.040$20,000
    03/12/2015Robert Bishop36,072$0.081$2,922

    Click here for the last 20 transactions all companies

    Directors & Executives (current)

    NAMETITLEDATE OF APPT
    Roger AstonExecutive Chairman12/08/2013
    Wayne BestIndependent Director12/11/2004
    Sam WrightNon Exec Director01/10/2008
    David MorrisNon Exec Director12/08/2013
    Neville BassettNon Exec Director02/10/2018
    Robert BishopExecutive Director29/10/2013

    Date of first appointment, title may have changed.

    Directors & Executives (former)

    NAMETITLEDATE OF APPOINTMENTDATE OF RESIGNATION
    Richard HopkinsCEO07/03/201725/05/2018
    Henry GulevNon Exec Director23/08/200729/10/2013
    Bryant McLartyExecutive Chairman25/07/200312/08/2013
    Gregory CunnoldNon Exec Director12/07/201107/11/2012

    Date of first appointment, title may have changed.